Human African TrypanosomiasisResearch

 

  • Target disease: HAT
  • Main partners (since project start): Anacor Pharmaceuticals Inc., Pace University, USA; The Laboratory of Microbioloy, Parasitology, and Hygiene, University of Antwerp, Belgium; SCYNEXIS Inc., USA.
  • Project start: April 2007 and April 2009, respectively
  • Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands;  Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations & individuals.

 

Overall Objective:

  • Maintain back-up oxaboroles which could replace the drug candidate acoziborole in case it does not succeed in development.

 

Extensive pharmacokinetic profiling of possible oxaborole compounds led to the selection of SCYX-1608210 and SCYX‑1330682, which demonstrated cure in the stage 2 mouse model of HAT, as a backup for SCYX-7158 in case of need. Given the current success of other projects for HAT, further development was put on hold in 2013 and will only recommence should problems be encountered with SCYX-7158 in clinical development.

 

To ensure future development options if needed, DNDi continues to provide support and advice to researchers working on the discovery of new candidates for HAT, and maintains two back-up candidates from the oxaborole class, both having demonstrated cure for stage-2 of the disease in a murine model.

 

Last update: August 2018